Advertisement
| neurocytonix treatment cost: Cellular Transplantation Craig Halberstadt, Dwaine F. Emerich, 2011-10-10 There have been tremendous strides in cellular transplantation in recent years, leading to accepted practice for the treatment of certain diseases, and use for many others in trial phases. The long history of cellular transplantation, or the transfer of cells from one organism or region of the body to another, has been revolutionized by advances in stem cell research, as well as developments in gene therapy. Cellular Transplants: From Lab to Clinic provides a thorough foundation of the basic science underpinning this exciting field, expert overviews of the state-of-the-art, and detailed description of clinical success stories to date, as well as insights into the road ahead. As highlighted by this timely and authoritative survey, scale-up technologies and whole organ transplantation are among the hurdles representing the next frontier. The contents are organized into four main sections, with the first covering basic biology, including transplant immunology, the use of immunosuppressive drugs, stem cell biology, and the development of donor animals for transplantation. The next part looks at peripheral and reconstructive applications, followed by a section devoted to transplantation for diseases of the central nervous system. The last part presents efforts to address the key challenges ahead, such as identifying novel transplantable cells and integrating biomaterials and nanotechnology with cell matrices. - Provides detailed description of clinical trials in cell transplantation - Review of current therapeutic approaches - Coverage of the broad range of diseases addressed by cell therapeutics - Discussion of stem cell biology and its role in transplantation |
| neurocytonix treatment cost: Cerebral Palsy Freeman Miller, Steven Bachrach, Nancy Lennon, Margaret E. O'Neil, 2020-11-05 Dr. Miller’s valuable resource helps members of the medical team navigate the complexity of cerebral palsy care by explaining unfamiliar treatments that fall outside of their own disciplines. Readers also benefit from a review of current practices in their own fields. Includes recommended treatment algorithms and is designed to help improve decision making. Written in a very conversational style and illustrated with lots of color the volume provides rehabilitational (part 1) and surgical aspects (part 2). Accomplished by a CD-ROM which provides lots of case studies - including walking analysis. The most comprehensive title on this topic written by a leading expert. |
| neurocytonix treatment cost: Children and Youth with Complex Cerebral Palsy Laurie Glader, Richard Stevenson, 2019-02-26 Children with complex cerebral palsy (typically, but not always, GMFCS levels IV and V) require skilled management and extensive expertise which can be overwhelming or intimidating for many clinical practitioners. This book explores management of the many medical comorbidities these children encounter, including orthopedic concerns, mobility and equipment needs, cognition and sensory impairment, difficult behaviors, seizures, respiratory complications and nutritional challenges, among many others. Summary points at the end of each chapter provide at-a-glance access to key recommendations. In addition, an Appendix provides adaptable care tools to guide clinicians in evaluation, preventive care and crisis management. Importantly, the book includes contributions from parents of children with cerebral palsy and youth with cerebral palsy, providing unique and critical wisdom for family-centred care. Parents and families of children and youth with complex cerebral palsy will particularly appreciate the inclusion of chapters on adolescence, transition to adulthood, and growing up, growing well with cerebral palsy. |
| neurocytonix treatment cost: Hyperkinetic Movement Disorders Alberto Albanese, Joseph Jankovic, 2012-03-07 Hyperkinetic movement disorders comprise a range of diseases characterized by unwanted and uncontrollable, or poorly controllable, involuntary movements. The phenomenology of these disorders is quite variable encompassing chorea, tremor, dystonia, myoclonus, tics, other dyskinesias, jerks and shakes. Discerning the underlying condition can be very difficult given the range and variability of symptoms. But recognizing the phenomenology and understanding the pathophysiology are essential to ensure appropriate treatment. Hyperkinetic Movement Disorders provides a clinical pathway for effective diagnosis and management of these disorders. The stellar international cast of authors distils the evidence so you can apply it into your practice. The judicious use of diagnostic criteria algorithms rating scales management guidelines Provides a robust framework for clear patient management. Throughout the text, QR codes* provide smartphone access to case-study videos of hyperkinetic symptoms. Purchase includes an enhanced Wiley Desktop Edition.* This is an interactive digital version featuring: all text and images in fully searchable form integrated videos of presentations View a sample video: www.wiley.com/go/albanese highlighting and note taking facilities book marking linking to additional references Hyperkinetic Movement Disorders provides you with the essential visual and practical tools you need to effectively diagnose and treat your patients. *Full instructions for using QR codes and for downloading your digital Wiley DeskTop Edition are inside the book. |
| neurocytonix treatment cost: Pharmacological Treatment of Tics Andrea E. Cavanna, 2020 Seignot's 1961 scientific report of a case of Tourette syndrome effectively treated with Haloperidol promoted a further 'paradigm shift' from the psychoanalytic theories to the current genetic and neurochemical theories on the aetiology and pathogenesis of Tourette syndrome. Seignot's observation was replicated throughout the world, starting with Caprini and Melotti's case report, which was published in the same year. The introduction of a pharmacological agent to control tics led to the speculation about a neurochemical substrate upon which medications work. Specifically, the unprecedented success of Haloperidol in controlling tics by blocking dopamine receptors in the brain suggested that might therefore be an excess of dopaminergic neurotransmission. American psychiatrists Arthur and Elaine Shapiro promoted the description of Tourette syndrome as a neurological disorder that by definition stood in opposition to psychoanalytic claims. The psychoanalytic perspective was successfully challenged in a book on Tourette syndrome published by the Shapiros in 1978. This paradigm shift in turn kindled interest in tracing the genetic basis of Tourette syndrome, a line of research which has flourished since the 1970s. Throughout the 1980s, studies on other first generation antidopaminergic medications, as well as alpha-2 adrenergic medications, were published, whereas in the 1990s the second generation of antidopaminergic medications were developed. During the first decade of the new millennium, Aripiprazole (sometimes referred to as 'third generation antidopaminergic medication') was first shown to be characterized by good efficacy and tolerability in the treatment of tics. More recently, a range of other medications belonging to different pharmaceutical classes have been investigated in patients with Tourette syndrome. The vast majority of these medications are pharmacological agents initially developed to treat other neuropsychiatric conditions-- |
| neurocytonix treatment cost: Neuropsychiatric Disorders Koho Miyoshi, Yasushi Morimura, Kiyoshi Maeda, 2014-11-02 Around the world societies are facing growing aging populations with the concomitant increase in neuropsychiatric disorders. Neuropsychiatric disorders are organic brain diseases with psychiatric symptoms, as in Alzheimer’s and Parkinson’s diseases, that cause cognitive impairment, including dementia, amnesic syndrome, and personality–behavioral changes. As a clinical science, neuropsychiatry aims to explore the complex interrelationship between behavior and brain function from a variety of perspectives, including those of psychology, neurology, and psychiatry. This concise and updated monograph comprises the latest findings in the field and includes chapters on delusional symptoms, mood disorders and neurotic symptoms, cognitive impairment, behavioral and personality changes, and recently, cerebral alterations revealed in PTSD patients and in endogenous psychoses through neuroimaging and neuropathology. These findings will certainly widen the realm of neuropsychiatry going forward and will prove of great value to specialists as well as to academics and trainees in neurology, psychiatry, neuropsychology, neuroradiology, neuropathology, neurophysiology, neurochemistry, and clinical genetics. Ultimately, neuropsychiatry aims to prevent and reduce the suffering of individuals with the psychiatric symptoms of cerebral disorders. |
| neurocytonix treatment cost: The Cost of Medical Care American Medical Association. Commission on the Cost of Medical Care, 1964 |
| neurocytonix treatment cost: Information on Payments for Cost of Treatment of Patients in State Hospitals Illinois. Department of Mental Health, 1965 |
| neurocytonix treatment cost: Report of the National Commission on the Cost of Medical Care National Commission on the Cost of Medical Care, 1978 |
| neurocytonix treatment cost: The Cost of Determining the Marginal Efficacy of Emperically Supported Treatments , 2012 The preponderance of evidence demonstrates that over time, whenever two or more psychosocial treatments are directly compared for depression and anxiety disorders, they achieve similar outcomes (Cuijpers, van Straten, Andersson, & van Oppen, 2008; Wampold, 2001). Yet, the National Institute of Mental Health (NIMH) has continued to fund efficacy trials that directly compare two psychotherapies with the specific purpose of finding differential treatment effects. The overall research costs of this approach have never been contrasted with the resulting benefits. This investigation used meta-analytic procedures to directly compare the costs of NIMH funded efficacy trials with the benefits as defined by relative treatment outcome. Studies published in peer-reviewed journals between the years of 1992-2009 were examined and the respective NIMH award was obtained from government databases. Effect sizes were also converted to a Number Needed to Treat (NNT) metric. Eight studies resulting in a total of nine comparisons were meta-analyzed. Results indicate the true difference between treatments compared in this meta-analysis was approximately zero. Furthermore, two post hoc analyses suggest individual classes of bona fide treatments produce equal outcomes when compared with Prolonged Exposure and Cognitive Therapy, respectively. Implications for mental health research and policy are discussed. |
| neurocytonix treatment cost: Report of the Commission on the Cost of Medical Care: Changing patterns of hospital care American Medical Association. Commission on the Cost of Medical Care, 1964 |
| neurocytonix treatment cost: The Five-Year Program of the Committee on the Cost of Medical Care Committee on the Cost of Medical Care (WASHINGTON, D.C.), 1928 |
Repairing the Brain, Restoring Lives - NeuroCytonix
Jul 3, 2024 · NeuroCytonix is working to meet the growing need of addressing neurological conditions by boldly innovating personalized, regenerative medicine designed to help regrow …
NeuroCytonix, Inc. - J Roberto Trujillo - Chairman and CEO ...
Dr. Trujillo founded NeuroCytonix in 2017 as a biomedical technology company exploring and researching innovative solutions for neurological disorders. The company is headquartered in …
NeuroCytonix Completes Clinical Trial of its NeuroCytotron ...
Jan 30, 2023 · NeuroCytonix has built a Research Center in Monterrey Mexico where it has trained and directed a clinical research team who has successfully implemented its first …
What is known about the treatment offered by NeuroCytonix ...
May 15, 2025 · Explore NeuroCytonix's Functional Neurogenesis Stimulation, a treatment aiming to enhance brain cell regeneration. Learn about its potential benefits and ongoing research.
NeuroCytonix Mexico: Our Clinical Research Center - NeuroCytonix
Learn about NeuroCytonix Mexico's clinical research center, where we conduct our protocols and study their potential outcomes
NeuroCytonix Webinar: Revolutionary Tissue ... - Entoro
Jun 25, 2020 · NeuroCytonix Inc. has developed a first-in-class platform using tissue regeneration therapy to treat incurable neurological conditions including Cerebral Palsy, Stroke, …
Neurocytotron on Cerebral Palsy
Mar 25, 2025 · Study treatment with Neurocytotron, which is a device is designed to generate a controlled beam of electromagnetic waves of certain frequencies in the presence of a …
NeuroCytonics Science - J Roberto Trujillo - Chairman and CEO ...
Neurocytonix’s technology uses safe, low-spectrum radio frequencies to generate instantaneous electromagnetic fields to increase the functionality of non-functioning or damaged nerve cells. …
NeuroCytonix Completes Clinical Trial of its NeuroCytotron ...
Jan 30, 2023 · NeuroCytonix is an emerging biotechnology business founded in January 2017 by Dr. J Roberto Trujillo to develop and exploit transformational medical technologies for the …
Network of Spencer Marsden, Analysis of 23 relations ...
NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non …
Repairing the Brain, Restoring Lives - NeuroCytonix
Jul 3, 2024 · NeuroCytonix is working to meet the growing need of addressing neurological conditions by boldly innovating personalized, regenerative medicine designed to help regrow …
NeuroCytonix, Inc. - J Roberto Trujillo - Chairman and CEO ...
Dr. Trujillo founded NeuroCytonix in 2017 as a biomedical technology company exploring and researching innovative solutions for neurological disorders. The company is headquartered in …
NeuroCytonix Completes Clinical Trial of its NeuroCytotron ...
Jan 30, 2023 · NeuroCytonix has built a Research Center in Monterrey Mexico where it has trained and directed a clinical research team who has successfully implemented its first …
What is known about the treatment offered by NeuroCytonix ...
May 15, 2025 · Explore NeuroCytonix's Functional Neurogenesis Stimulation, a treatment aiming to enhance brain cell regeneration. Learn about its potential benefits and ongoing research.
NeuroCytonix Mexico: Our Clinical Research Center - NeuroCytonix
Learn about NeuroCytonix Mexico's clinical research center, where we conduct our protocols and study their potential outcomes
NeuroCytonix Webinar: Revolutionary Tissue ... - Entoro
Jun 25, 2020 · NeuroCytonix Inc. has developed a first-in-class platform using tissue regeneration therapy to treat incurable neurological conditions including Cerebral Palsy, Stroke, …
Neurocytotron on Cerebral Palsy
Mar 25, 2025 · Study treatment with Neurocytotron, which is a device is designed to generate a controlled beam of electromagnetic waves of certain frequencies in the presence of a …
NeuroCytonics Science - J Roberto Trujillo - Chairman and CEO ...
Neurocytonix’s technology uses safe, low-spectrum radio frequencies to generate instantaneous electromagnetic fields to increase the functionality of non-functioning or damaged nerve cells. …
NeuroCytonix Completes Clinical Trial of its NeuroCytotron ...
Jan 30, 2023 · NeuroCytonix is an emerging biotechnology business founded in January 2017 by Dr. J Roberto Trujillo to develop and exploit transformational medical technologies for the …
Network of Spencer Marsden, Analysis of 23 relations ...
NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non …
